Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Summary
What This Bill Does
The bill creates improvements to program for grants for research on therapies for ALS Section 2(b) of the Accelerating Access to Critical Therapies for ALS Act (21 U.S.C, provides report on ALS and other rare neurodegenerative disease action plans Section 4 of the Accelerating Access to Critical Therapies for ALS Act (21 U.S.C, and requires GAO report Section 6 of the Accelerating Access to Critical Therapies for ALS Act (Public Law 117–79) is amended, in the matter preceding paragraph (1)— by striking 4 years after the date of the enactment. It relies on reporting requirements, compliance mandates, definition changes, and grants. The main policy areas are Health, Healthcare, and Science & Space.
Who Benefits and How
Public beneficiaries or protected communities affected by the clause could face reduced risk, Researchers and scientific institutions affected by the bill could gain revenue opportunities, and Patients and health care consumers affected by the bill could gain revenue opportunities.
Who Bears the Burden and How
Federal, state, or local agencies responsible for implementing the clause would take on compliance duties and Regulated entities and members of the public affected by the bill would take on compliance duties.
Key Provisions
- Creates improvements to program for grants for research on therapies for ALS Section 2(b) of the Accelerating Access to Critical Therapies for ALS Act (21 U.S.C.
- Provides report on ALS and other rare neurodegenerative disease action plans Section 4 of the Accelerating Access to Critical Therapies for ALS Act (21 U.S.C.
- Requires GAO report Section 6 of the Accelerating Access to Critical Therapies for ALS Act (Public Law 117–79) is amended, in the matter preceding paragraph (1)— by striking 4 years after the date of the enactment...
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
The bill creates improvements to program for grants for research on therapies for ALS Section 2(b) of the Accelerating Access to Critical Therapies for ALS Act (21 U.S.C, provides report on ALS and other rare neurodegenerative disease action plans Section 4 of the Accelerating Access to Critical Therapies for ALS Act (21 U.S.C, and requires GAO report Section 6 of the Accelerating Access to Critical Therapies for ALS Act (Public Law 117–79) is amended, in the matter preceding paragraph (1)— by striking 4 years after the date of the enactment.
Key Policy Areas
Health, Healthcare, Science & Space
Primary Purpose
The bill creates improvements to program for grants for research on therapies for ALS Section 2(b) of the Accelerating Access to Critical Therapies for ALS Act (21 U.S.C, provides report on ALS and other rare neurodegenerative disease action plans Section 4 of the Accelerating Access to Critical Therapies for ALS Act (21 U.S.C, and requires GAO report Section 6 of the Accelerating Access to Critical Therapies for ALS Act (Public Law 117–79) is amended, in the matter preceding paragraph (1)— by striking 4 years after the date of the enactment.
Policy Domains
Whole bill
Identified Gains
- Public beneficiaries or protected communities affected by the clause
- Researchers and scientific institutions affected by the bill
- Patients and health care consumers affected by the bill
Identified Costs
- Federal, state, or local agencies responsible for implementing the clause
- Regulated entities and members of the public affected by the bill
Sponsors
Legislative Progress
ReportedCommittee on Health, Education, Labor, and Pensions. Ordered to be …
Read twice and referred to the Committee on Health, Education, …
Introduced in Senate
Ms. Murkowski (for herself and Mr. Coons) introduced the following …
Impact analysis is available but no clear stakeholder effects identified. View clause-level analysis →
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology